Journal profile · Biochemistry, Genetics and Molecular Biology-Molecular Biology
Molecular Therapy-Methods & Clinical Development
ISSN 2329-0501 · eISSN 3117-387X · Cell Press · ENGLAND
Molecular Therapy-Methods & Clinical Development: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 5.04; fully open access; APC about USD 3,900; median 170 days to acceptance (80 articles, last 24 months); 230 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Molecular Therapy-Methods & Clinical Development is published by Cell Press and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Virus-based gene therapy research, CRISPR and Genetic Engineering and CAR-T cell therapy research, together about 47.2% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Molecular Therapy Advances is a peer-reviewed, open-access journal publishing transformative research across the full spectrum of gene and cell therapy. Formerly published as Molecular Therapy Methods & Clinical Development, the journal has evolved to reflect its expanded scope and renewed focus on field-defining science, from foundational discoveries to translational breakthroughs and early clinical advances. As an official journal of the American Society of Gene & Cell Therapy (ASGCT), it serves as a trusted platform for both ASGCT members and the broader scientific community.The journal reflects the accelerating pace of molecular medicine, where emerging technologies and cross-disciplinary approaches are reshaping the therapeutic landscape. We publish research that drives this momentum, emphasizing advances in gene delivery, genome and epigenome editing, engineered immune and stem cells, biomanufacturing, and both viral and non-viral vector platforms, alongside preclinical and clinical studies that move these innovations closer to patients. We also recognize the growing influence of computational science and artificial intelligence, which are redefining how therapies are designed, optimized and brought into clinical practice.We welcome studies across a broad range of diseases, from rare acquired and inherited disorders to more common conditions, when they offer meaningful mechanistic insight or therapeutic innovation. Submissions should demonstrate advancement in biological understanding, therapeutic potential, or translational impact. We particularly encourage work that challenges assumptions, reveals unexpected biology, or addresses persistent barriers in therapy development. High-quality negative results, replication studies, and methodological innovations are also valued when they strengthen rigor and reproducibility. Our mission is to elevate impactful science and provide a home for both established leaders and emerging voices shaping the future of gene and cell therapy.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Molecular Biology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology25.7%
- CRISPR and Genetic EngineeringBiochemistry, Genetics and Molecular Biology11.7%
- CAR-T cell therapy researchMedicine9.8%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology9.6%
- Viral Infectious Diseases and Gene Expression in InsectsBiochemistry, Genetics and Molecular Biology7.1%
- Viral Infections and Immunology ResearchMedicine3.6%
- Retinal Development and DisordersBiochemistry, Genetics and Molecular Biology2.9%
- Lysosomal Storage Disorders ResearchMedicine2.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: noReview journal: no
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.04LetPub ·
- Impact factor (publisher)
- 5Publisher website ·
- CiteScore 2026-06
- 7.7LetPub ·
- CiteScore (publisher)
- 7.7Publisher website ·
- SJR 2026-06
- 1.75LetPub ·
- SNIP 2026-06
- 1.05LetPub ·
- h-index
- 20LetPub ·
- h-index
- 94OpenAlex ·
- i10-index
- 1,207OpenAlex ·
- 2-year mean citedness
- 7.02OpenAlex ·
- Self-citation rate
- 8%LetPub ·
- Share of gold OA articles
- 90.58%LetPub ·
Volume
- Articles per year
- 148LetPub ·
Articles by year OpenAlex count · 1,835 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2025 | 230 | 230 | 1,203 |
| 2024 | 206 | 206 | 1,857 |
| 2023 | 194 | 194 | 2,708 |
| 2022 | 172 | 172 | 3,607 |
| 2021 | 190 | 190 | 5,463 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
170 daysMedian, submission to acceptance · P25–P75 125 days – 223 days
- Acceptance to online
- median 4 days (80 articles)
- Submission to online
- median 173 days
- Sample
- 80 articles with submission and acceptance dates (296 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Submission to first decision
- 7 daysPublisher website ·
- First decision after review
- 43 daysPublisher website ·
- Submission to acceptance
- 145 daysPublisher website ·
- Acceptance to publication
- 4 daysPublisher website ·
- Submission to publication (journal-reported)
- about 24 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,900 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,900 / EUR 3,610 / GBP 3,120 / JPY 483,720 | — | — | |
| LetPub | USD 3,900 | Yes | — | |
| Publisher website | USD 3,900 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
Article Publishing Charge (APC): USD 3,900 (excluding taxes). Review this journal’s open access policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Cell Press
- Country or region
- ENGLAND
- Language
- English
- ISSN
- 2329-0501
- Electronic ISSN
- 3117-387X
- Society / sponsor
- American Society of Gene & Cell Therapy
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Molecular Therapy-Methods & Clinical Development
What CAS zone is Molecular Therapy-Methods & Clinical Development in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular Therapy-Methods & Clinical Development is in Zone 2 of Medicine, and in Zone 2 of the minor category Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Therapy-Methods & Clinical Development?
The latest impact factor listed by LetPub is 5.04; CiteScore 7.7, h-index 94.
How long does peer review take at Molecular Therapy-Methods & Clinical Development?
Based on the dates recorded on 80 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 170 days (interquartile range 125–223 days); authors report an average review time of about 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Molecular Therapy-Methods & Clinical Development?
According to LetPub and DOAJ records, Molecular Therapy-Methods & Clinical Development is indexed in Scopus and DOAJ.
Is Molecular Therapy-Methods & Clinical Development open access, and what is the APC?
Molecular Therapy-Methods & Clinical Development is a fully open-access journal. APC about USD 3,900.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .